Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Oct 1;100(7):1708–1715. doi: 10.1172/JCI119695

A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

K Okuda 1, A D'Andrea 1, R A Etten 1, J D Griffin 1
PMCID: PMC508353  PMID: 9312168

Abstract

The BCR/ABL oncogene encodes an activated tyrosine kinase that causes human chronic myelogenous leukemia. The mechanism of transformation, however, is complex and not well understood. One of the important contributions of BCR to transformation is believed to be dimerization or oligomerization of ABL, thereby activating ABL tyrosine kinase activity. We reasoned that if ABL was dimerized through other mechanisms, activation of the tyrosine kinase activity should also result, and the activated kinase may also be transforming. Erythropoietin is known to activate its receptor by causing dimerization, and therefore a synthetic oncogene was created by linking the extracytoplasmic and transmembrane domains of the EPO receptor with c-ABL. This chimeric receptor was stably expressed in Ba/F3 cells and, in the absence of EPO, had no detectable biological effect on the cells. EPO, however, induced a rapid, dose-dependent activation of ABL tyrosine kinase activity and phosphorylation of several cellular proteins. The major target proteins have been identified, and are very similar to the known substrates of BCR/ABL, including Shc, CBL, CRKL, and several proteins in the cytoskeleton. EPO treatment also resulted in biological effects that were remarkably similar to those of BCR/ABL, including improved viability, altered integrin function, and a weak mitogenic signal. The biological effects were in part dose-dependent, in that low EPO concentrations enhanced viability but did not cause proliferation. At high EPO doses, kinase activation was maximal, and a mitogenic effect was also revealed. In nude mice, Ba/F3 cells expressing this chimeric receptor did not cause detectable disease without administration of pharmacologic doses of EPO. If EPO was given intraperitoneally 5 days a week, however, a dose-dependent lethal leukemia resulted. This ligand-regulatable oncogene mimics some of the biological effects of BCR/ABL, and analysis of ABL mutants in this system will be useful to dissect the signaling pathways that cause CML.

Full Text

The Full Text of this article is available as a PDF (370.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoniou C. E., Thien C. B., Langdon W. Y. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J. 1994 Oct 3;13(19):4515–4523. doi: 10.1002/j.1460-2075.1994.tb06773.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barber D. L., DeMartino J. C., Showers M. O., D'Andrea A. D. A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Mol Cell Biol. 1994 Apr;14(4):2257–2265. doi: 10.1128/mcb.14.4.2257-2265.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barber D. L., Mason J. M., Fukazawa T., Reedquist K. A., Druker B. J., Band H., D'Andrea A. D. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood. 1997 May 1;89(9):3166–3174. [PubMed] [Google Scholar]
  4. Bazzoni G., Carlesso N., Griffin J. D., Hemler M. E. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996 Jul 15;98(2):521–528. doi: 10.1172/JCI118820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ben-Neriah Y., Bernards A., Paskind M., Daley G. Q., Baltimore D. Alternative 5' exons in c-abl mRNA. Cell. 1986 Feb 28;44(4):577–586. doi: 10.1016/0092-8674(86)90267-9. [DOI] [PubMed] [Google Scholar]
  6. Carlesso N., Frank D. A., Griffin J. D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996 Mar 1;183(3):811–820. doi: 10.1084/jem.183.3.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carlesso N., Griffin J. D., Druker B. J. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 1994 Jan;9(1):149–156. [PubMed] [Google Scholar]
  8. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985 Jan-Mar;4(1):87–90. doi: 10.1002/sim.4780040112. [DOI] [PubMed] [Google Scholar]
  9. D'Andrea A. D., Lodish H. F., Wong G. G. Expression cloning of the murine erythropoietin receptor. Cell. 1989 Apr 21;57(2):277–285. doi: 10.1016/0092-8674(89)90965-3. [DOI] [PubMed] [Google Scholar]
  10. D'Andrea A. D., Yoshimura A., Youssoufian H., Zon L. I., Koo J. W., Lodish H. F. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol. 1991 Apr;11(4):1980–1987. doi: 10.1128/mcb.11.4.1980-1987.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. D'Andrea A. D., Yoshimura A., Youssoufian H., Zon L. I., Koo J. W., Lodish H. F. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol. 1991 Apr;11(4):1980–1987. doi: 10.1128/mcb.11.4.1980-1987.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Daley G. Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9312–9316. doi: 10.1073/pnas.85.23.9312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Damen J., Mui A. L., Hughes P., Humphries K., Krystal G. Erythropoietin-induced tyrosine phosphorylations in a high erythropoietin receptor-expressing lymphoid cell line. Blood. 1992 Oct 15;80(8):1923–1932. [PubMed] [Google Scholar]
  14. Druker B., Okuda K., Matulonis U., Salgia R., Roberts T., Griffin J. D. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 1;79(9):2215–2220. [PubMed] [Google Scholar]
  15. Gabert J., Thuret I., Carcassonne Y., Maraninchi D., Mannoni P. Residual bcr/abl transcripts in chronic myeloid leukaemia. Lancet. 1990 Feb 17;335(8686):417–418. doi: 10.1016/0140-6736(90)90258-7. [DOI] [PubMed] [Google Scholar]
  16. Gishizky M. L., Witte O. N. BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. Curr Top Microbiol Immunol. 1992;182:65–72. doi: 10.1007/978-3-642-77633-5_8. [DOI] [PubMed] [Google Scholar]
  17. Gobert S., Porteu F., Pallu S., Muller O., Sabbah M., Dusanter-Fourt I., Courtois G., Lacombe C., Gisselbrecht S., Mayeux P. Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction. Blood. 1995 Jul 15;86(2):598–606. [PubMed] [Google Scholar]
  18. Golub T. R., Barker G. F., Bohlander S. K., Hiebert S. W., Ward D. C., Bray-Ward P., Morgan E., Raimondi S. C., Rowley J. D., Gilliland D. G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4917–4921. doi: 10.1073/pnas.92.11.4917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Golub T. R., Goga A., Barker G. F., Afar D. E., McLaughlin J., Bohlander S. K., Rowley J. D., Witte O. N., Gilliland D. G. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996 Aug;16(8):4107–4116. doi: 10.1128/mcb.16.8.4107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M., Greaves M. F. Adhesive defects in chronic myeloid leukemia. Curr Top Microbiol Immunol. 1989;149:151–155. doi: 10.1007/978-3-642-74623-9_14. [DOI] [PubMed] [Google Scholar]
  21. Gordon M. Y., Dowding C. R., Riley G. P., Goldman J. M., Greaves M. F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature. 1987 Jul 23;328(6128):342–344. doi: 10.1038/328342a0. [DOI] [PubMed] [Google Scholar]
  22. Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984 Jan;36(1):93–99. doi: 10.1016/0092-8674(84)90077-1. [DOI] [PubMed] [Google Scholar]
  23. Heisterkamp N., Knoppel E., Groffen J. The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. Nucleic Acids Res. 1988 Nov 11;16(21):10069–10081. doi: 10.1093/nar/16.21.10069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. 1985 Jun 27-Jul 3Nature. 315(6022):758–761. doi: 10.1038/315758a0. [DOI] [PubMed] [Google Scholar]
  25. Kelliher M., Knott A., McLaughlin J., Witte O. N., Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol. 1991 Sep;11(9):4710–4716. doi: 10.1128/mcb.11.9.4710-4716.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Krosl J., Damen J. E., Krystal G., Humphries R. K. Erythropoietin and interleukin-3 induce distinct events in erythropoietin receptor-expressing BA/F3 cells. Blood. 1995 Jan 1;85(1):50–56. [PubMed] [Google Scholar]
  27. Linnekin D., Evans G. A., D'Andrea A., Farrar W. L. Association of the erythropoietin receptor with protein tyrosine kinase activity. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6237–6241. doi: 10.1073/pnas.89.14.6237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lugo T. G., Pendergast A. M., Muller A. J., Witte O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990 Mar 2;247(4946):1079–1082. doi: 10.1126/science.2408149. [DOI] [PubMed] [Google Scholar]
  29. Maru Y., Witte O. N. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991 Nov 1;67(3):459–468. doi: 10.1016/0092-8674(91)90521-y. [DOI] [PubMed] [Google Scholar]
  30. Matsuguchi T., Salgia R., Hallek M., Eder M., Druker B., Ernst T. J., Griffin J. D. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18;269(7):5016–5021. [PubMed] [Google Scholar]
  31. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., Miyajima A., Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997 May 1;89(9):3148–3154. [PubMed] [Google Scholar]
  32. Matulonis U., Salgia R., Okuda K., Druker B., Griffin J. D. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct;21(11):1460–1466. [PubMed] [Google Scholar]
  33. McWhirter J. R., Galasso D. L., Wang J. Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993 Dec;13(12):7587–7595. doi: 10.1128/mcb.13.12.7587-7595.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. McWhirter J. R., Wang J. Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol. 1991 Mar;11(3):1553–1565. doi: 10.1128/mcb.11.3.1553-1565.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Melo J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996 Oct 1;88(7):2375–2384. [PubMed] [Google Scholar]
  36. Muller A. J., Young J. C., Pendergast A. M., Pondel M., Landau N. R., Littman D. R., Witte O. N. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991 Apr;11(4):1785–1792. doi: 10.1128/mcb.11.4.1785-1792.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Okuda K., Golub T. R., Gilliland D. G., Griffin J. D. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996 Sep 19;13(6):1147–1152. [PubMed] [Google Scholar]
  38. Papadopoulos P., Ridge S. A., Boucher C. A., Stocking C., Wiedemann L. M. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 1995 Jan 1;55(1):34–38. [PubMed] [Google Scholar]
  39. Pendergast A. M., Muller A. J., Havlik M. H., Maru Y., Witte O. N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991 Jul 12;66(1):161–171. doi: 10.1016/0092-8674(91)90148-r. [DOI] [PubMed] [Google Scholar]
  40. Pendergast A. M., Quilliam L. A., Cripe L. D., Bassing C. H., Dai Z., Li N., Batzer A., Rabun K. M., Der C. J., Schlessinger J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993 Oct 8;75(1):175–185. [PubMed] [Google Scholar]
  41. Salgia R., Brunkhorst B., Pisick E., Li J. L., Lo S. H., Chen L. B., Griffin J. D. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21;11(6):1149–1155. [PubMed] [Google Scholar]
  42. Salgia R., Li J. L., Ewaniuk D. S., Pear W., Pisick E., Burky S. A., Ernst T., Sattler M., Chen L. B., Griffin J. D. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 1;100(1):46–57. doi: 10.1172/JCI119520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Salgia R., Sattler M., Pisick E., Li J. L., Griffin J. D. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb;24(2):310–313. [PubMed] [Google Scholar]
  44. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M. A., Pisick E., Xu G., Li J. L., Prasad K. V., Griffin J. D. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15;12(4):839–846. [PubMed] [Google Scholar]
  45. Shimizu R., Komatsu N., Nakamura Y., Nakauchi H., Nakabeppu Y., Miura Y. Role of c-jun in the inhibition of erythropoietin receptor-mediated apoptosis. Biochem Biophys Res Commun. 1996 May 6;222(1):1–6. doi: 10.1006/bbrc.1996.0688. [DOI] [PubMed] [Google Scholar]
  46. Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985 Jun 13;315(6020):550–554. doi: 10.1038/315550a0. [DOI] [PubMed] [Google Scholar]
  47. Stam K., Heisterkamp N., Grosveld G., de Klein A., Verma R. S., Coleman M., Dosik H., Groffen J. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med. 1985 Dec 5;313(23):1429–1433. doi: 10.1056/NEJM198512053132301. [DOI] [PubMed] [Google Scholar]
  48. Van Etten R. A., Jackson P. K., Baltimore D., Sanders M. C., Matsudaira P. T., Janmey P. A. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol. 1994 Feb;124(3):325–340. doi: 10.1083/jcb.124.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Verfaillie C. M., McCarthy J. B., McGlave P. B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest. 1992 Oct;90(4):1232–1241. doi: 10.1172/JCI115985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Watowich S. S., Hilton D. J., Lodish H. F. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol. 1994 Jun;14(6):3535–3549. doi: 10.1128/mcb.14.6.3535-3549.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. de Klein A., van Kessel A. G., Grosveld G., Bartram C. R., Hagemeijer A., Bootsma D., Spurr N. K., Heisterkamp N., Groffen J., Stephenson J. R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982 Dec 23;300(5894):765–767. doi: 10.1038/300765a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES